Bookmark and Share

$GNPX Positive Preclinical Data on Non-Small Cell Lung Cancer Treatment

  • Genprex’s collaborators at MD Anderson reported positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody for the treatment of non-small cell lung cancer
  • The TUSC2 gene, a tumor suppressor gene, is the active agent in Genprex’s Oncoprex immunogene therapy, the company’s lead drug candidate for the treatment of lung cancer
  • In combination with pembrolizumab, the TUSC2 gene significantly slowed tumor growth in mice with human immune cells
  • Lung cancer ranks among the malignancies that are expected to increase the most in the coming years, especially among women; immunotherapy solutions may provide an effective option for the treatment of such cancers

Genprex Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, reported in a press release that its University of Texas MD Anderson Cancer Center collaborators have recorded positive preclinical data in a lung cancer treatment study (http://nnw.fm/8E4bC). The results of the study, which analyzed the combination of the TUSC2 gene and anti-PD1 antibody pembrolizumab, were presented in a poster at the 2019 American Association of Cancer Research Meeting. TUCS2 is a tumor suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy.

The poster data showed that TUCS2 in combination with checkpoint blockade was more effective than checkpoint blockade alone in increasing the survival of mice with…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX

 

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, April 18th, 2019 Uncategorized
Top Small Cap Market News